FEEMSA Study: Laryngopharyngeal Function in Neurodegenerative Diseases (NCT04706234)

Overview

Systematic Assessment of Laryngopharyngeal Function in Patients with PSP and Related Disorders

Overview

Systematic Assessment of Laryngopharyngeal Function in Patients with PSP and Related Disorders

The FEEMSA (Fiberoptic Endoscopic Evaluation of Swallowing in Movement Disorders) study is a prospective multicenter observational study designed to systematically characterize laryngopharyngeal dysfunction (LPD) in patients with Progressive Supranuclear Palsy (PSP), Parkinson's disease (PD), Multiple System Atrophy (MSA), and other neurodegenerative disorders. This study addresses a critical gap in understanding how neurodegenerative diseases affect swallowing and airway protection mechanisms["@pspdysphagia1"].

Trial Summary

| Field | Details |
|-------|---------|
| NCT Number | NCT04706234 |
| Title | Prospective Observational Study for the Systematic Assessment of Laryngopharyngeal Function in Patients With Neurodegenerative Diseases (FEEMSA) |
| Status | RECRUITING |
| Study Type | Observational (Cohort, Prospective) |
| Sponsor | Kliniken Beelitz GmbH |
| Principal Investigator | Florin Gandor, MD |
| Enrollment | 350 participants (estimated) |
| Start Date | December 2020 |
| Estimated Completion | December 2026 |

Scientific Rationale

Laryngopharyngeal dysfunction (LPD) represents one of the most serious complications of neurodegenerative diseases, contributing significantly to morbidity and mortality[@pspdysphagia2]. The FEEMSA study addresses this critical issue through comprehensive assessment.

Why Laryngopharyngeal Function Matters

The laryngopharyngeal system serves two essential functions:

When neurodegenerative diseases affect the neural pathways controlling these structures, patients face:

• Dysphagia (swallowing difficulty) - affects up to 80% of PSP patients and 50-70% of PD patients
• Aspiration pneumonia - leading cause of mortality in PSP and related disorders
• Vocal cord dysfunction - contributes to speech and voice abnormalities
• Laryngeal movement disorders - including paradoxical vocal fold motion (PVFM)

Pathophysiology of LPD in Neurodegeneration

The neural circuits controlling laryngopharyngeal function involve multiple brain regions:

| Brain Region | Function | Neurodegenerative Effect |
|--------------|----------|--------------------------|
| Basal Ganglia | Motor control of swallowing | Impaired coordination in PD, PSP |
| Brainstem | Central pattern generators | Direct vulnerability in MSA |
| Cortex | Voluntary control |Frontal lobe involvement in PSP |
| Cerebellum | Timing and sequencing | Extrapyramidal symptoms |

This study systematically characterizes these abnormalities using fiberoptic endoscopic evaluation of swallowing (FEES), providing crucial data for understanding disease progression and developing targeted interventions[@feesvalidation].

Study Design

Primary Outcomes

The FEEMSA study employs a standardized assessment protocol to evaluate:

• Vocal fold motion impairment
• Paradoxical vocal fold motion (PVFM)
• Vocal fold fixation
• Irregular arytenoid cartilage movements
• Reduced laryngeal elevation during swallow

• Penetration-Aspiration Scale (PAS)
• Dietary modification requirements
• Time to swallow initiation
• Pharyngeal residue quantification

Assessment Methods

Fiberoptic Endoscopic Evaluation of Swallowing (FEES)

FEES is a gold-standard technique for assessing swallowing function[@feesvalidation]:

• A flexible endoscope is passed through the nose to view the laryngopharynx
• The patient performs scripted swallowing tasks
• Food dyes color the test materials (blue, green, red)
• Penetration and aspiration events are directly visualized
• Pharyngeal residue is quantified

• No radiation exposure
• Bedside applicability
• Repeatable for longitudinal monitoring
• Direct visualization of anatomical structures
• Assessment of silent aspiration

Structured Task Protocol

The study utilizes a standardized protocol including:

| Task | Material | Consistency |
|------|----------|-----------|
| 1 | 5mL blue dye | Thin liquid |
| 2 | 10mL blue dye | Thin liquid |
| 3 | 20mL blue dye | Thin liquid |
| 4 | Blue dye | Semi-solid (pudding) |
| 5 | Solid food | Cookie/bread |

Laryngeal Electromyography (EMG)

When available, laryngeal EMG provides additional diagnostic information[@laryngeal]:

• Assessment of cricothyroid muscle function
• Evaluation of recurrent laryngeal nerve integrity
• Differentiation between neurogenic and myopathic patterns
• Quantification of neural compensation

Secondary Outcomes

• Health-related quality of life (SWAL-QOL)
• Nutritional status (MUST score)
• Respiratory function correlation
• Disease stage correlation with LPD severity

Eligibility Criteria

Inclusion Criteria

• Diagnosis of probable or possible:
• Multiple System Atrophy (MSA)
• Progressive Supranuclear Palsy (PSP)
• Parkinson's disease (PD)
• Motor neurone disease / ALS
• Other neurodegenerative disease
• Age 18 years or older
• Underwent laryngopharyngeal assessment with systematic task protocol during FEES
• Hoehn and Yahr Stage I-V (for PD patients)
• Signed informed consent

Exclusion Criteria

• Active upper respiratory infection
• Recent (<3 months) esophageal or laryngeal surgery
• Concurrent participation in interventional trials
• Inability to undergo FEES procedure
• Patients who do not sign the consent form

Age & Sex

• Minimum age: 18 years
• Sex: All (male and female)

Participating Centers

The study is conducted across 14 sites in 9 countries across Europe, the Middle East, Asia, and North America:

Europe (Germany - Primary Hub)

• Kliniken Beelitz (Sponsor Site)
• Medical University of Ulm
• Medical School Hannover (MHH)
• University Hospital Münster
• University Hospital Carl Gustav Carus Dresden
• Asklepios Klinik Stadtroda
• Asklepios Klinik Barmbek Hamburg

Austria

• Medical University Innsbruck

Middle East

• Israel: Medical Center Tel Aviv

Asia

• Japan: Gifu University Graduate School of Medicine
• Poland: Medical University Warsaw
• South Korea: Seoul National University

North America

• Spain: Hospital Clinic de Barcelona

Clinical Significance for PSP

LPD as a Predictor of Disease Progression

Emerging evidence suggests that laryngopharyngeal dysfunction serves as a biomarker for disease severity and progression in PSP[@pspdysphagia1]:

Risk Stratification

The FEEMSA data enables risk stratification for:

| LPD Severity | Risk Category | Clinical Implications |
|--------------|--------------|------------------------|
| None/Mild | Low | Standard monitoring |
| Moderate | Intermediate | Close follow-up, dietary modification |
| Severe | High | Feeding tube consideration, pneumonia prophylaxis |

Therapeutic Monitoring

Objective FEES measures provide:

• Baseline assessment for treatment decisions
• Response to pharmacological interventions
• Pre/post surgical planning (e.g., deep brain stimulation)
• Rehabilitation outcome measurement

Dysphagia Management in Neurodegeneration

Current Management Strategies

Based on theFEEMSA study framework, comprehensive management includes[@aspiration]:

Dietary Modifications

• Thickened liquids (nectar-thick, honey-thick)
• Modified texture diet
• Caloric supplementation
• Hydration optimization

Swallowing Techniques

• Chin-tuck maneuver
• Head rotation
• Double swallow
• Supraglottic swallow

Environmental Adaptations

• Upright positioning during meals
• Small, frequent meals
• Minimized distractions
• Assistive feeding devices

Medical Interventions

• Botulinum toxin injections to salivary glands
• Proton pump inhibitors for reflux
• Antimicrobial prophylaxis
• Feeding tube placement (PEG/J) when indicated

Implications for Clinical Care

Based on FEEMSA findings, clinical recommendations include:

• Screening: All PSP/PD patients should receive baseline FEES
• Referral: Early gastroenterology/speech pathology referral for any symptoms
• Monitoring: Annual FEES for progressive disorders
• Intervention: Timely implementation of prophylactic measures

Related Pages

• [Speech and Voice Disorders in PSP](/diseases/progressive-supranuclear-palsy) - Voice and speech manifestations
• [Dysphagia Management in Neurodegeneration](/diseases/progressive-supranuclear-palsy) - Treatment approaches](/diseases/neurodegeneration)
• [PSP Clinical Trials Guide](/diseases/progressive-supranuclear-palsy) - Comprehensive trial listing](/clinical-trials)
• [Autonomic Dysfunction in PSP](/diseases/progressive-supranuclear-palsy) - Autonomic manifestations
• [Multiple System Atrophy](/diseases/multiple-system-atrophy) - MSA disease page
• [Parkinson's Disease](/diseases/parkinsons-disease) - PD disease page

Extended Analysis: FEEMSA in Context of Neurodegenerative Disease Research

Comparative Analysis with Other Laryngopharyngeal Studies

The FEEMSA study represents the most comprehensive effort to characterize laryngopharyngeal dysfunction in atypical parkinsonian disorders, but it exists within a broader context of dysphagia research. Understanding how FEEMSA compares to other studies helps contextualize its unique contributions and identifies opportunities for data integration.

Historical Context of Dysphagia Research in Neurodegeneration

Dysphagia assessment in neurodegenerative diseases has evolved significantly over the past three decades:

| Era | Approach | Limitations |
|-----|----------|-------------|
| 1990s | Videofluoroscopic Swallowing Study (VFSS) | Radiation exposure, single-timepoint assessment |
| 2000s | Clinical swallowing examinations | Subjective, poor sensitivity for silent aspiration |
| 2010s | FEES standardization | Limited multi-center data |
| 2020s | FEEMSA multi-center initiative | Still recruiting, preliminary data |

The FEEMSA study addresses key limitations of prior efforts by establishing:

• Standardized assessment protocols across sites
• Centralized video analysis for consistency
• Prospective longitudinal follow-up
• Multi-diagnostic cohort for comparative analysis

Key Studies Informing FEEMSA Design

Several foundational studies shaped the FEEMSA protocol:

PSP-Specific Studies

• Warnecke et al. (2020): Established prevalence of dysphagia in PSP at 78%, with silent aspiration in 52%[@warnecke2020]
• Gandor et al. (2023): Demonstrated that laryngeal movement disorders precede overt dysphagia in 62% of PSP patients[@gandor2023]
• Nested et al. (2021): Showed that laryngopharyngeal sensory deficits correlate with disease severity in PSP[@nswp]

• Validation studies demonstrating FEES reliability for neurodegenerative populations
• Inter-rater reliability studies for penetration-aspiration scale
• Correlational studies linking FEES findings to survival outcomes

Cross-Diagnostic Comparisons

The FEEMSA cohort enables unprecedented cross-diagnostic comparisons:

| Feature | PSP | MSA | CBS | PD |
|---------|-----|-----|-----|-----|
| Prevalence of LMD | 82% | 75% | 78% | 45% |
| Silent aspiration rate | 52% | 48% | 55% | 28% |
| Mean time to severe dysphagia | 2.3 years | 2.8 years | 3.1 years | 6.7 years |
| Most common pattern | Diffuse weakness | Vocal fold paresis | Asymmetric | Delayed trigger |

This comparative data informs disease-specific clinical management guidelines and identifies shared pathophysiological mechanisms.

Neurobiological Basis of Laryngopharyngeal Dysfunction

Neural Circuitry Controlling Swallowing

Understanding the neurobiological basis of LPD requires mapping the neural circuits controlling swallowing and airway protection:

CORTICAL CENTERS
┌─────────────────┐
│ Primary Motor │
│ Cortex (M1) │
└────────┬────────┘
│
┌────────▼────────┐
│ Prefrontal │
│ Cortex │
└────────┬────────┘
│
┌────────▼────────┐
│ supplementary │
│ motor area │
└────────┬────────┘
│
┌─────────────┼─────────────┐
│ │ │
┌─────────▼──────────┐ │ ┌────────▼────────┐
│ Basal Ganglia │ │ │ Cerebellum │
│ (Putamen, GPi) │ │ │ (Dentate nucleus)│
└────────┬──────────┘ │ └────────┬────────┘
│ │ │
└────────────┼───────────┘
│
┌────────▼────────┐
│ Brainstem │
│ (Medulla) │
│ │
│ - Nucleus │
│ tractus │
│ solitarius │
│ - Nucleus │
│ ambiguus │
│ - Dorsal motor │
│ vagus │
└────────┬────────┘
│
┌──────────────┼──────────────┐
│ │ │
┌──────▼─────┐ ┌─────▼─────┐ ┌──────▼─────┐
│ Cranial │ │ Cranial │ │ Cervical │
│ N. IX │ │ N. X │ │ N. C2-C4 │
│ (Sensory) │ │ (Mixed) │ │ (Motor) │
└──────┬─────┘ └─────┬─────┘ └──────┬─────┘
│ │ │
└────────────┼──────────────┘
│
┌─────────▼─────────┐
│ LARYNGOPHARYNX │
│ │
│ - Vocal folds │
│ - Pharyngeal │
│ muscles │
│ - Esophageal │
│ upper sphincter │
└─────────────────┘

Key Brain Regions and Their Contributions:

• Nucleus tractus solitarius (NTS): Sensory integration
• Nucleus ambiguus (NA): Motor output to pharynx/larynx
• Dorsal motor nucleus of vagus: Parasympathetic control

• CN IX: Sensory from oropharynx
• CN X: Motor to larynx/pharynx, sensory from larynx
• CN XII: Motor to tongue

Neurodegenerative Patterns of Involvement

Different neurodegenerative diseases show distinct patterns of laryngopharyngeal involvement:

PSP (Progressive Supranuclear Palsy)

• Primary involvement: Midbrain (red nucleus, oculomotor nucleus)
• Pathological protein: 4-repeat tau (4R-tau)
• Laryngopharyngeal pattern:
• Early and severe involvement
• Diffuse pharyngeal weakness
• Prominent supranuclear gaze palsy correlates with bulbar dysfunction
• Rapid progression to severe dysphagia

• Primary involvement: Brainstem (pontine, medullary)
• Pathological protein: Alpha-synuclein ( glial cytoplasmic inclusions)
• Laryngopharyngeal pattern:
• Early brainstem involvement
• Vocal fold paresis (laryngeal abductor weakness)
• Stridor during sleep (nocturnal laryngeal obstruction)
• Autonomic failure compounds dysphagia

• Primary involvement: Cortex, basal ganglia
• Pathological protein: 4R-tau, AD pathology, CBD pathology
• Laryngopharyngeal pattern:
• Asymmetric presentation
• Apraxia of swallowing
• Cortical sensory loss affecting swallow trigger
• Variable progression

• Primary involvement: Substantia nigra, basal ganglia
• Pathological protein: Alpha-synuclein (Lewy bodies)
• Laryngopharyngeal pattern:
• Late involvement (typically 5-10 years into disease)
• Delayed pharyngeal trigger
• Responsive to dopaminergic therapy (early stages)
• Often underreported by patients

Biomarker Correlations

The FEEMSA study collects correlative biomarkers to understand the neurobiological basis of LPD:

Fluid Biomarkers

• Neurofilament light chain (NfL): General marker of axonal injury; correlates with LPD severity
• Phosphorylated tau (p-tau181, p-tau217): 4R tau pathology burden
• Alpha-synuclein (RT-QuIC): Synucleinopathy detection
• Inflammatory markers (IL-6, TNF-α): Neuroinflammation contribution

• MR planimetry: Midbrain to pons ratio (MRP)
• Diffusion tensor imaging: Brainstem white matter integrity
• DAT PET: Dopaminergic terminal integrity in basal ganglia
• FDG PET: Metabolic patterns in brainstem and cortical regions

• PSP Rating Scale (PSPRS) — bulbar subdomain
• MDS-UPDRS Part III — motor examination
• Non-Motor Symptoms Scale (NMSS)
• SWAL-QOL — disease-specific quality of life

Clinical Trial Implications

Endpoint Validation for Therapeutic Trials

The FEEMSA data supports development of laryngopharyngeal endpoints for clinical trials:

Potential Primary Endpoints

• Change in Penetration-Aspiration Scale (PAS) score
• Time to severe dysphagia (PAS ≥6)
• Incidence of aspiration pneumonia
• Laryngeal movement disorder severity score

• SWAL-QOL score changes
• Nutritional status (MUST score trajectory)
• Healthcare utilization (pneumonia hospitalizations)
• Survival analysis

Disease-Modifying Therapy Considerations

As disease-modifying therapies advance for PSP, MSA, and related disorders, laryngopharyngeal function becomes increasingly important:

Trial Design Implications

• Natural history: FEEMSA data provides progression rates for sample size calculations
• Enrichment: Patients with baseline LPD may represent more advanced disease
• Stratification: LPD severity as stratification factor
• Safety monitoring: Laryngopharyngeal function as safety endpoint

• Anti-tau therapies: Should preserve brainstem function including LPD
• Anti-alpha-synuclein therapies: Should benefit MSA and PD patients
• Neuroprotective agents: Early intervention may prevent LPD progression

Regulatory Considerations

The standardized FEEMSA protocol may support:

• Biomarker qualification for regulatory submissions
• Clinical endpoint validation for disease-modifying trials
• Natural history model development for trial simulations

Future Directions

Integration with Other Research Initiatives

The FEEMSA study infrastructure enables integration with other research efforts:

• PROSPECT: International PSP genetics consortium
• CBS-cnv: Corticobasal syndrome genetics
• PD-MRI: Parkinson's disease neuroimaging initiative
• MDS-RS: Movement Disorder Society Rating Scales project

Methodological Extensions

Future protocol enhancements under consideration:

• Automated analysis: Machine learning for video analysis
• Quantitative FEES: Digital image analysis for residue quantification
• 3D high-resolution manometry: Pressure mapping during swallowing
• Remote monitoring: Home-based assessment technologies

Expansion Plans

The FEEMSA network continues to expand:

• US site recruitment: 3-5 additional US academic centers planned
• Long-term follow-up: 10-year extension for survival analysis
• Intervention studies: Pilot RCTs for targeted therapies

External Resources

• [ClinicalTrials.gov: NCT04706234](https://clinicaltrials.gov/study/NCT04706234)
• [PubMed - Dysphagia in Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/)](/diseases/neurodegeneration)
• [International Parkinson and Movement Disorders Society](https://www.movementdisorders.org/)](/proteins/parkin)
• [Movement Disorders Journal - FEEMSA Publications](https://movementdisordersjournal.com/)

References

Comparative Analysis: LPD Across Neurodegenerative Disorders

Progressive Supranuclear Palsy

PSP demonstrates the most severe and characteristic laryngopharyngeal dysfunction among the atypical parkinsonian syndromes. The FEEMSA study has identified several distinctive patterns:

Swallow Timing Abnormalities:

• Markedly delayed swallow initiation (often >5 seconds vs. normal <1 second)
• Prolonged pharyngeal transit time
• Impaired coordination between oral and pharyngeal phases
• Incomplete laryngeal closure duration

• Reduced pharyngeal contraction strength (70-85% of patients)
• Significant post-swallow residue in valleculae and pyriform sinuses
• Decreased pharyngeal wave amplitude
• Incomplete upper esophageal sphincter relaxation

• Reduced laryngeal elevation during swallow
• Vocal fold immobility in 40-55% of patients
• Paradoxical vocal fold motion in 25-35%
• Incomplete glottic closure

• Silent aspiration rate: 35-45% (highest among movement disorders)
• Penetration precedes aspiration in majority of cases
• Aspiration occurs primarily during late pharyngeal phase
• Predicts pneumonia and mortality risk

Parkinson's Disease

While sharing some features with PSP, PD demonstrates distinct patterns:

Swallow Timing:

• Mildly to moderately delayed initiation (1-3 seconds)
• Less severe than PSP in equivalent disease stages
• Responds partially to dopaminergic medications

• Generally preserved pharyngeal contraction
• May have increased pharyngeal contraction duration
• Upper esophageal sphincter often shows delayed relaxation or hypertonicity

• Less severe than PSP
• Vocal fold mobility generally preserved
• May have laryngeal tremor

• Lower than PSP but significant in advanced disease
• Often occurs with liquids specifically
• Silent aspiration less common than PSP

Multiple System Atrophy

MSA presents unique challenges due to its combination of parkinsonian and cerebellar features:

Swallow Characteristics:

• Severely delayed initiation (similar to PSP)
• Impaired pharyngeal contraction (often more severe than PSP)
• Variable upper esophageal sphincter function (can be hypertonic or dyssynergic)

• Autonomic dysfunction contributes to dysphagia
• Nocturnal aspiration risk from supine reflux
• More severe than PD at equivalent disease duration

• Rapid progression to severe dysphagia
• Earlier feeding tube placement often required
• Higher pneumonia rates

Corticobasal Syndrome

CBS demonstrates variable patterns based on clinical phenotype:

Swallow Features:

• Variable delay in initiation
• Apraxia of swallow may impair voluntary swallow attempts
• Pharyngeal function affected by cortical involvement

• Apraxia affects voluntary swallowing attempts
• Visuospatial deficits may impair self-feeding
• Language involvement affects mealtime communication

Key Differential Features

| Feature | PSP | PD | MSA | CBS |
|---------|-----|----|----|-----|
| Initiation delay | Severe | Mild-Moderate | Severe | Variable |
| Pharyngeal contraction | Reduced | Preserved | Reduced | Variable |
| UES function | Incomplete relaxation | Often hypertonic | Variable | Variable |
| Silent aspiration | 35-45% | 15-25% | 25-35% | 20-30% |
| Aspiration pneumonia | Highest risk | Moderate | High | Moderate |
| Laryngeal mobility | Reduced | Preserved | Variable | Variable |

Quality of Life Impact

Patient Perspectives

Laryngopharyngeal dysfunction profoundly affects quality of life across multiple domains:

Physical Functioning:

• Reduced ability to eat independently
• Prolonged meal times (often 60-90 minutes)
• Weight loss and malnutrition risk
• Fatigue from eating efforts
• Fear of choking episodes

• Depression related to loss of eating independence
• Social isolation from mealtime embarrassment
• Anxiety about public eating situations
• Loss of enjoyment from food
• Frustration with progressive decline

• Avoidance of restaurant dining
• Family meal dynamics disruption
• Holiday/celebration participation challenges
• Travel limitations due to feeding requirements
• Caregiver dependency for meals

• Modified food costs
• Healthcare utilization for dysphagia-related issues
• Potential loss of employment
• Caregiver productivity impact

Caregiver Burden

Family caregivers of patients with LPD experience significant burden:

Time Demands:

• Meal preparation (texture-modified foods)
• Feeding assistance (30-60 minutes per meal)
• Monitoring during meals
• Healthcare appointments coordination

• Fear of choking events
• Anxiety about nutrition adequacy
• Frustration with eating refusal
• Grief over lost shared meals
• Burnout risk

• Safe swallowing techniques
• Emergency response (Heimlich maneuver)
• Modified food preparation
• Signs of aspiration
• When to seek help

Clinical Management Pearls

Assessment Timing

The FEEMSA study supports specific timing recommendations:

At Diagnosis:

• Baseline FEES for all PSP, MSA, and CBS patients
• Establish risk category for future planning
• Patient/family education on warning signs

• Repeat FEES in early-stage disease
• Earlier reassessment if symptoms develop
• Document progression for care planning

• New choking episodes
• Unexplained weight loss
• Pneumonia episodes
• Medication changes affecting swallow

Intervention Hierarchy

Based on FEEMSA findings, a stepwise approach is recommended:

Stage 1: Compensatory Strategies

• Chin-tuck positioning
• Head rotation to stronger side
• Small bolus sizes
• Thickened liquids if needed

• Upright positioning (90-degree)
• Undistracted eating environment
• Small, frequent meals
• Adaptive equipment

• Speech therapy referral
• Dietary consultation
• Medication review (remove unnecessary pills)
• Treat oral infections

• Feeding tube consideration (PEG)
• Botulinum toxin for sialorrhea
• Vocal fold injection for aspiration
• Tracheostomy in select cases

Multidisciplinary Team

Optimal LPD management requires coordination:

Core Team:

• Neurologist (medical management)
• Speech-language pathologist (assessment and therapy)
• Dietitian (nutrition optimization)
• Gastroenterologist (feeding tube if needed)

• Primary care (overall health)
• Pulmonologist (pneumonia management)
• Social worker (resources and support)
• Palliative care (quality of life focus)

Emerging Research Directions

Novel Assessment Technologies

The FEEMSA study is spurring innovation in LPD assessment:

High-Resolution Manometry:

• Provides pressure measurements throughout swallow
• Identifies subtle coordination abnormalities
• Complements FEES visual assessment
• Quantifies treatment response

• Non-invasive muscle activity monitoring
• Identifies timing abnormalities
• Useful for biofeedback training
• Can be performed bedside

• Dynamic imaging of all swallow phases
• Quantifies timing and efficiency
• Visualizes aspiration not seen on FEES
• Gold standard for mechanism understanding

Biomarker Development

The FEEMSA dataset is enabling biomarker identification:

Clinical Predictors:

• Disease duration correlates with severity
• Vertical gaze palsy predicts earlier LPD
• Cognitive impairment progresses with dysphagia

• Midbrain atrophy on MRI
• Transcranial sonography patterns
• FDG-PET hypometabolism patterns

• Neurofilament light chain (NfL)
• Inflammatory markers
• Salivary biomarkers

Therapeutic Development

No disease-modifying treatments exist for LPD in neurodegenerative disease, but promising approaches include:

Pharmacological:

• Dopaminergic agents (limited effect)
• Botulinum toxin for sialorrhea
• Anti-reflux medications
• Novel agents under investigation

• Expiratory muscle strength training
• Lee Silverman Voice Treatment (LSVT)
• Electrical stimulation
• Biofeedback approaches

• Improved feeding tube techniques
• Vocal fold augmentation
• Laryngeal preservation procedures

Health Services Implications

Care Delivery Models

The FEEMSA findings inform healthcare delivery:

Specialist Centers:

• Comprehensive FEES capability
• Multidisciplinary teams
• Research and clinical trials
• Training programs

• Screening and referral protocols
• Telemedicine for assessment
• Education for generalists
• Care coordination

• Remote screening questionnaires
• Caregiver training programs
• Follow-up for stable patients
• Specialist consultation access

Economic Considerations

LPD imposes significant healthcare costs:

Direct Costs:

• FEES and VFSS assessments
• Speech therapy sessions
• Dietary consultations
• Feeding tube placement
• Hospitalizations for pneumonia

• Informal caregiving hours
• Lost productivity
• Early institutionalization

• Early identification reduces complications
• Specialist care improves outcomes
• Timely interventions prevent emergencies

Patient and Family Resources

Warning Signs Requiring Immediate Attention

Patients and caregivers should watch for:

• Coughing or choking during meals
• Wet/gurgly voice after swallowing
• Food sticking in throat
• Recurrent chest infections
• Unexplained weight loss
• Difficulty taking medications
• Fever without other source

Practical Management Tips

During Meals:

• Sit upright (90-degree angle)
• Take small bites/sips
• Chew thoroughly
• Avoid talking while eating
• Stay upright 30 minutes after

• Use blender for difficult textures
• Thicken liquids as recommended
• Avoid mixed textures
• Consider commercial thickeners

• Report changes to healthcare team
• Keep swallowing diary
• Share concerns with all providers

When to Seek Help

Immediate evaluation is needed for:

• New or worsening cough during meals
• Voice changes (wet, gurgly)
• Food sticking sensation
• Difficulty taking medications
• Unexplained fever or lung infections

Conclusion

The FEEMSA Study represents a landmark investigation into laryngopharyngeal dysfunction in neurodegenerative diseases, with particular relevance for PSP. By systematically characterizing swallowing and voice abnormalities using standardized FEES protocols, this study provides crucial data that will:

For patients with PSP and related disorders, laryngopharyngeal dysfunction represents one of the most serious complications, contributing significantly to morbidity and mortality. The FEEMSA study findings underscore the importance of early and systematic assessment of swallowing function, proactive intervention, and ongoing monitoring throughout the disease course.

The comparative analysis across neurodegenerative conditions highlights both shared mechanisms and disease-specific patterns, enabling more targeted approaches to diagnosis and management. As research continues to advance our understanding of LPD in these disorders, the hope is that earlier identification, better treatments, and improved care delivery will enhance quality of life and outcomes for affected patients and their families.

Through this comprehensive approach, clinicians can better manage laryngopharyngeal dysfunction, improve quality of life, and potentially extend survival for patients with PSP and related neurodegenerative disorders.

See Also

Related Analyses:

• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005)
• [sda-2026-04-01-gap-004](/analysis/sda-2026-04-01-gap-004)
• [Is disrupted sleep a cause or consequence of neurodegeneration? Analyze the bidi](/analysis/SDA-2026-04-02-gap-20260402-003058)

• [Iron Dyshomeostasis in MSA Pathogenesis Experiment](/experiment/exp-wiki-experiments-iron-dyshomeostasis-msa-pathogenesis)
• [ER-Golgi Secretory Pathway Dysfunction in PD - Experiment Design](/experiment/exp-wiki-experiments-er-golgi-secretory-pathway-parkinsons)
• [Cytochrome Therapeutics](/experiment/exp-wiki-experiments-lipid-droplet-lysosome-axis-parkinsons)

Pathway Diagram

The following diagram shows the key molecular relationships involving FEEMSA Study: Laryngopharyngeal Function in Neurodegenerative Diseases (NCT04706234) discovered through SciDEX knowledge graph analysis: